CN104363915A - 麻痹性贝类毒素 - Google Patents

麻痹性贝类毒素 Download PDF

Info

Publication number
CN104363915A
CN104363915A CN201380014664.7A CN201380014664A CN104363915A CN 104363915 A CN104363915 A CN 104363915A CN 201380014664 A CN201380014664 A CN 201380014664A CN 104363915 A CN104363915 A CN 104363915A
Authority
CN
China
Prior art keywords
psp
gtx
pruritus
humans
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380014664.7A
Other languages
English (en)
Chinese (zh)
Inventor
马克斯·拉特曼
让·雅克·皮洛格特
吉米·斯特伯格
沃夫冈·万斯切特
康斯坦扎·西格拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHYTOTOX SpA
Original Assignee
PHYTOTOX SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHYTOTOX SpA filed Critical PHYTOTOX SpA
Publication of CN104363915A publication Critical patent/CN104363915A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380014664.7A 2012-03-16 2013-03-15 麻痹性贝类毒素 Pending CN104363915A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12159932.8 2012-03-16
EP12159932.8A EP2638908A1 (en) 2012-03-16 2012-03-16 Paralytic Shellfish Poison
US201261613601P 2012-03-21 2012-03-21
US61/613,601 2012-03-21
PCT/EP2013/055448 WO2013135884A1 (en) 2012-03-16 2013-03-15 Paralytic shellfish poison

Publications (1)

Publication Number Publication Date
CN104363915A true CN104363915A (zh) 2015-02-18

Family

ID=45874715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014664.7A Pending CN104363915A (zh) 2012-03-16 2013-03-15 麻痹性贝类毒素

Country Status (12)

Country Link
US (1) US9593120B2 (https=)
EP (2) EP2638908A1 (https=)
JP (1) JP6196638B2 (https=)
KR (1) KR20140138958A (https=)
CN (1) CN104363915A (https=)
AU (1) AU2013234287B2 (https=)
BR (1) BR112014022921B8 (https=)
CA (1) CA2866795C (https=)
ES (1) ES2645999T3 (https=)
PL (1) PL2825172T3 (https=)
RU (1) RU2633637C2 (https=)
WO (1) WO2013135884A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105259292A (zh) * 2015-11-12 2016-01-20 上海市农业科学院 一种测定水产品中麻痹性贝类毒素的方法
CN108949847A (zh) * 2018-08-01 2018-12-07 浙江海洋大学 一种利用海洋细菌发酵制备膝沟藻毒素的方法
CN109061031A (zh) * 2018-08-15 2018-12-21 浙江海洋大学 微小亚历山大藻代谢产物－膝沟藻毒素的分离纯化方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775594B1 (fr) * 1998-03-06 2002-12-27 Oreal Utilisation d'un compose inhibant l'activite d'un canal sodium ou d'un canal calcium dans une composition a usage topique
WO2005110417A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
CN1323081C (zh) * 2005-01-19 2007-06-27 南开大学 二步树脂法制备河豚毒素的方法及河豚毒素制剂
US20060194759A1 (en) * 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
CA2652669A1 (en) * 2006-06-09 2007-12-21 Merck & Co., Inc. Benzazepinones as sodium channel blockers
WO2010111777A1 (en) * 2009-03-30 2010-10-07 Wex Medical Limited Novel sodium channel blocking compounds tetrodotoxin galactopyranosides
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARIA WIESE等: "Neurotoxic Alkaloids: Saxitoxin and Its Analogs", 《MARINE DRUGS》 *
孟宪梅等: "石房蛤毒素研究及应用进展", 《食品科技》 *
孟宪梅等: "石房蛤毒素研究及应用进展", 《食品科技》, vol. 35, no. 8, 31 December 2010 (2010-12-31), pages 150 - 154 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105259292A (zh) * 2015-11-12 2016-01-20 上海市农业科学院 一种测定水产品中麻痹性贝类毒素的方法
CN108949847A (zh) * 2018-08-01 2018-12-07 浙江海洋大学 一种利用海洋细菌发酵制备膝沟藻毒素的方法
CN108949847B (zh) * 2018-08-01 2021-06-18 浙江海洋大学 一种利用海洋细菌发酵制备膝沟藻毒素的方法
CN109061031A (zh) * 2018-08-15 2018-12-21 浙江海洋大学 微小亚历山大藻代谢产物－膝沟藻毒素的分离纯化方法

Also Published As

Publication number Publication date
BR112014022921B1 (pt) 2021-07-27
JP6196638B2 (ja) 2017-09-13
JP2015509971A (ja) 2015-04-02
EP2638908A1 (en) 2013-09-18
RU2633637C2 (ru) 2017-10-16
US9593120B2 (en) 2017-03-14
CA2866795A1 (en) 2013-09-19
HK1205934A1 (en) 2015-12-31
CA2866795C (en) 2021-01-12
EP2825172A1 (en) 2015-01-21
PL2825172T3 (pl) 2018-01-31
BR112014022921B8 (pt) 2022-03-29
EP2825172B8 (en) 2017-12-20
KR20140138958A (ko) 2014-12-04
BR112014022921A2 (https=) 2017-06-20
AU2013234287B2 (en) 2017-06-29
ES2645999T3 (es) 2017-12-11
AU2013234287A1 (en) 2014-11-06
US20150065528A1 (en) 2015-03-05
WO2013135884A1 (en) 2013-09-19
RU2014141341A (ru) 2016-05-10
EP2825172B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CN101198362B (zh) 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法
KR20190003535A (ko) 전달 시스템
KR20100047840A (ko) 디클로페낙의 신규한 비수용성 국소 용액 및 이를 제조하는 과정
EP1644004A2 (en) Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
JP2014511382A (ja) フルマゼニル錯体、それを含む組成物、およびその使用
CA2521152A1 (en) Use of a topical medicament comprising riluzole
BR112015006790B1 (pt) Composição tópica e uso de cetoprofeno
JP2017081920A (ja) サキシトキシン誘導体での触覚の喪失の処置
CN101489541A (zh) 多胺在治疗银屑病中的应用
BR112021002656A2 (pt) composições oleaginosas tópicas
CN104363915A (zh) 麻痹性贝类毒素
WO2024013283A1 (fr) Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement
JPH04500824A (ja) 光老化の作用を回復させるための皮膚の治療方法
US20230310528A1 (en) Deep eutectic solvent including one or more active pharmaceutical ingredients derived from mushrooms
JP4393552B2 (ja) ピリドンカルボン酸誘導体を含有するローション剤
CN117813117A (zh) 一种芦可替尼组合物及其用途
Sheu et al. Simultaneous optimization of percutaneous delivery and adhesion for ketoprofen poultice
US20180055838A1 (en) Methods and compositions for treatment of dermal and epidermal wounds
CN101460172B (zh) 别嘌醇在制备治疗手足综合征的药物中的用途
CN116966129A (zh) 稳定的局部用非诺多泮组合物
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
JP2004099486A (ja) フリーラジカル性疾患用外用剤
HK1205934B (en) Paralytic shellfish poison for the treatment of itch
WO2016079262A1 (fr) Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne
KR20000066357A (ko) 케토롤락 외용제제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Santiago, Chile

Applicant after: PHYTOTOX SPA

Address before: Santiago, Chile

Applicant before: PHYTOTOX SPA

COR Change of bibliographic data
RJ01 Rejection of invention patent application after publication

Application publication date: 20150218

RJ01 Rejection of invention patent application after publication